2026-03-16 20:10:09
Kyntra Bio Reports Q4 and Full Year 2025 Financial Results with Positive Developments
Expected Stock impact: Slightly Positive
Kyntra Bio, Inc. (Nasdaq: KYNB) announced its financial results for the fourth quarter and full year ended December 31, 2025, revealing total revenue of $1.3 million for Q4 and $6.4 million for the full year, a significant decrease from $3.1 million and $29.6 million in the respective periods of 2024. The company reported a net loss of $14.6 million, or $3.61 per share, for Q4 2025, compared to a net loss of $8.7 million, or $2.15 per share, in Q4 2024. For the full year, the net loss was $58.2 million, or $14.40 per share, down from a net loss of $153.1 million, or $38.26 per share, in 2024. Despite these losses, Kyntra Bio highlighted several positive developments in its pipeline. The Phase 2 monotherapy trial of FG-3246, an antibody-drug conjugate targeting CD46 in metastatic castration-resistant prostate cancer, is actively enrolling and on track for interim analysis in the second half of 2026. Additionally, positive results from an investigator-sponsored study of FG-3246 in combination with enzalutamide were presented at the 2026 ASCO GU, reinforcing the trial's design. The company has also submitted a pivotal Phase 3 clinical trial protocol for roxadustat for treating anemia in patients with lower-risk myelodysplastic syndromes to the FDA. Kyntra Bio reported cash, cash equivalents, investments, and accounts receivable totaling $109.4 million, providing a cash runway into 2028. The management team will host a conference call and webcast presentation to discuss these results and provide further updates.
